KMDA Stock Analysis: Buy, Sell, or Hold?
KMDA - Kamada Ltd
$7.83
0.01 (0.13%)
▲
5d:
+1.56%
30d:
-5.32%
90d:
-11.82%
HOLD
MODERATE Confidence
Analysis Updated: May 22, 2026 12:00 AM ET
Earnings: May 26, 2026
TODAY
Get Alerted When KMDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: KMDA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: KMDA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$18.75
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.64
32.7% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 15.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KMDA is currently trading at $7.83, which is considered oversold relative to its 30-day fair value range of $7.91 to $8.40. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.8) compared to its historical average (15.7). Remarkably, the market is currently pricing in an annual earnings decline of 6.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, KMDA is showing sideways momentum. Immediate support is located at $7.35, while resistance sits at $8.65.
Market Sentiment: KMDA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.00 (+66.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, KMDA is showing sideways momentum. Immediate support is located at $7.35, while resistance sits at $8.65.
Market Sentiment: KMDA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $13.00 (+66.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.91 -
$8.40
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 66.0% below Wall St target ($13.00)
Trading Range Analysis
30-Day Trading Range
$7.91 -
$8.40
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.35
Resistance Level
$8.65
Current Trend
Sideways
Technical data as of
May 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.77
Wall Street Target
$13.00
(+66.0%)
Revenue Growth (YoY)
2.8%
Profit Margin
11.2%
Valuation Discount vs History
-6.6% cheaper
PE vs Historical
12.8 vs 15.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.6%
(market-implied from PE analysis)
1-Year Target
$7.31
(-7%)
2-Year Target
$6.83
(-13%)
3-Year Target
$6.38
(-19%)
3-Yr Target (if PE normalizes)
(PE: 13→16)
$7.85
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 43.5%)
$39.82
(+409%)
Base:
(SPY PE: 12.8, Growth: 43.5%)
$23.12
(+195%)
Bear:
(PE: 10.9, Growth: 43.5%)
$19.65
(+151%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (22x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 22.34 | Current EPS (TTM): $0.35
Bull Case
$15.07
(+93%)
Analyst growth 75.2%, PE expands to 24.6
Base Case
$13.70
(+75%)
Market implied 75.2%, PE stable at 22.3
Bear Case
$5.32
(-32%)
Severe decline -20.0%, PE contracts to 19.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.8 to 15.7
Stabilization Target:
$9.63
(+23.0%)
PE Expansion Potential:
+23.0%
Share & Embed Analysis
Last updated: May 24, 2026 7:48 PM ET
Data refreshes hourly during market hours. Next update: 8:48 PM
Data refreshes hourly during market hours. Next update: 8:48 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KMDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 63 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 56 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
